Time To Act: Covid-19 & Cancer

Dr. Andrei Baciu was appointed Secretary of State within Romania’s Ministry of Health on December... Dr. Andrei Baciu was appointed Secretary of State within Romania’s Ministry of Health on December 2019. As such, he was delegated to support the coordination of COVID response in Romania, being actively involved in decision making process during the pandemic response. Also, he coordinates the national vaccination campaign roll out, acting as Vice-President of the National Vaccination Committee. Read more Show less

Dr. Jennifer L. Baker is a Senior Researcher and leader of the group on lifecourse epidemiology... Dr. Jennifer L. Baker is a Senior Researcher and leader of the group on lifecourse epidemiology at the Center for Clinical Research and Prevention, Copenhagen University Hospital system, in Denmark. Her research programme investigates how body size and growth during childhood in combination with other exposures across the lifecourse relate to disease. She and her group have shown that a higher body mass index in childhood increases the risk during adult life of numerous non-communicable diseases including nine types of cancer, cardiovascular disease and type 2 diabetes. Dr. Baker has authored over 100 peer-reviewed publications and has served on several international expert scientific committees. Dr. Baker is the co-chair for the European Association for the Study of Obesity Childhood Obesity Task Force. Read more Show less

Professor Karen Canfell is the inaugural Director of the Daffodil Centre, a joint venture between... Professor Karen Canfell is the inaugural Director of the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW. She is an epidemiologist, modeller, and a translationally-focused population health researcher. She has led evaluations of new cancer screening approaches for government agencies in several countries. She currently leads Compass, which is the first major international experience of cervical screening in an HPV-vaccinated population. Her team’s work underpins the 2017 transition of the National Cervical Screening Program in Australia from Pap smears to 5-yearly HPV-based screening. She currently has active collaborative modelling grants from the US NIH and WHO to model cervical cancer prevention in the USA and globally. Her work as one of the co-leads of the WHO Cervical Cancer Elimination Modelling Consortium was presented and discussed at the Executive Board of the World Health Assembly in 2020 and supported the formal resolution by WHO to support the cervical cancer elimination initiative, launched in late 2020. She is a Fellow of the Australian Academy of Health and Medical Sciences, the 2021 recipient of Cancer Australia’s Jeanne Ferris Award for her contributions to gynecological cancer research, and 2020 recipient of the NHMRC Elizabeth Blackburn Investigator Grant Award for Leadership in Health Services Research. Read more Show less

Professor Mark Lawler is Board Member, European Cancer Organisation and Special Network on the... Professor Mark Lawler is Board Member, European Cancer Organisation and Special Network on the Impact of COVID-19 on Cancer Co-Chair, Associate Pro-Vice-Chancellor, Professor of Digital Health, and Chair in Translational Cancer Genomics, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast (QUB). Mark is an internationally renowned scientist who has published over 200 papers including key publications in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer Discovery, Nature Comms, Gut). His work has been recognised by numerous national/international awards including the Vander Molen Prize for Leukaemia Research, Ely Lilly Prize, St Lukes Medal for Cancer Research, Graves Medal for Medical Research and the prestigious 2018 European Health Award. Mark is Associate Director of Health Data Research Wales-Northern Ireland, one of 6 Health Data Research UK (HDR-UK) Substantive Sites, which is driving innovative precision medicine and population health approaches through the use of Big Data. He is Scientific Director for DATA-CAN, the UK Health Data Research Hub for Cancer. In the wake of the Cambridge Analytica/Facebook scandal, Mark led a pan European group in developing a roadmap to restore public trust in health data, published in Lancet Oncology. In the context of the recent COVID-19 pandemic, Mark is employing a data-driven approach to understand and mitigate the effects of COVID-19 on cancer patients and cancer systems Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health, an international cooperative dedicated to effective and responsible sharing of genomic/clinical data. He authored a number of key papers, including a blueprint for cancer data sharing (Nature Medicine) and a call to action for a Global Cancer Data Knowledge Network (New Engl J Med). Mark is the Queen's Lead of the £5M Medical Research Council-Cancer Research UK funded Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in colorectal cancer (CRC). His international reputation in CRC was instrumental in his leading a Critical Gaps in CRC Research Initiative, published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most “hits” of any article in the journal). Mark is a member of the Board of the European Alliance for Personalised Medicine (EAPM) and led the development of EAPM’s research strategy. He is also a member of the Scientific Advisory Board of the European Cancer Patient Coalition and of the Strategic Advisory Board of Genomics England. Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was architect of the European Cancer Patient's Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been translated into 17 European languages and adopted in 25 European countries. It was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. The BoR received The 2018 European Health Award, a prestigious award for partnerships that yield real health impact in Europe which Mark received with ECCO colleagues during the 2018 European Health Forum Gastein, the premier European health policy conference. Mark’s has a particular interested in addressing cancer challenges in Central and Eastern Europe (CEE) and has highlighted the need for data-enabled research, including economic evaluation to empower cancer control strategies in the region. He is also committed to optimal pathology and laboratory medicine provision for citizens in resource-limited settings and was senior author of a paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries. He is leading the Lancet Oncology Groundshot Commission to provide the evidence base and road map for cancer research in Europe, with a particular focus on CEE countries, whose results will feed into the EU cancer mission. Read more Show less

Dr Mirjam Crul is Board Member, European Cancer Organisation, Special Network on the Impact of... Dr Mirjam Crul is Board Member, European Cancer Organisation, Special Network on the Impact of COVID-19 on Cancer Co-Chair and Workforce Network Co-Chair. Shereceived her master in pharmacy in 1999. Subsequently, she worked as a research fellow at the Netherlands Cancer Institute studying clinical pharmacology of novel anticancer agents. This work resulted in a PhD in 2002. She trained to become a Hospital Pharmacist from 2002-2006. Currently she is employed in the Amsterdam University Medical Center, where she is the Head of the Aseptic Compounding Unit and has pharmaceutical responsibility for the Oncology Department. She served as a Board Member for the Dutch Hospital Pharmacists Association (NVZA) from 2016 to 2019. At present, she holds a chair in the European Cancer Organisation Board and is Vice-President of the European Society of Oncology Pharmacy (ESOP). Read more Show less

Nathalie Moll joined the European Federation of Pharmaceutical Industries and Associations... Nathalie Moll joined the European Federation of Pharmaceutical Industries and Associations (EFPIA) as Director General in April 2017.Prior to joining EFPIA, between 2010 and 2017 Nathalie was the Secretary General of EuropaBio ranked as the most effective European Trade Association in Brussels in 2013. She spent over 20 years working for the biotech industry at EU and national level in associations and corporate positions and held the position of Chair and Vice Chair of the International Council of Biotech Associations (ICBA). In 2013, Nathalie won the Technovisionaries Women Innovation Award organised by Women & Technologies® while in 2009, Nathalie and the Green Biotech Team of EuropaBio were presented with the Leadership and Excellence in Advancing Ag-Biotech and Food Issues Award. Nathalie was also named one of the 15 leading women in biotech in Europe in 2017. Read more Show less

Robert Greene is Member, European Cancer Organisation's Patient Advisory Committee, he is a... Robert Greene is Member, European Cancer Organisation's Patient Advisory Committee, he is a consultant, speaker and patient advocate, supporting the development of patient relations. His interest revolves around patient empowerment, diversity, personalised healthcare, cancer-related malnutrition and health and healthcare disparities in prostate cancer. He is Board Member of the European Cancer Patient Coalition and Founder & President of the HungerNdThirst Foundation Read more Show less

Shadow Rapporteur, EU4HEALTH; Vice Chair of the Special Committee on Beating Cancer and Co-Chair,... Shadow Rapporteur, EU4HEALTH; Vice Chair of the Special Committee on Beating Cancer and Co-Chair, ENVI Committee Health Working Group Read more Show less